Devyser Diagnostics AB (publ) (DVYSR.ST)

SEK 117.0

(0.0%)

Revenue Summary of Devyser Diagnostics AB (publ)

Devyser Diagnostics AB (publ)'s latest annual revenue in 2023 was 169.3 Million SEK , up 33.71% from previous year.
Devyser Diagnostics AB (publ)'s latest quarterly revenue in 2024 Q1 was 50.7 Million SEK , up 11.67% from previous quarter.
Devyser Diagnostics AB (publ) reported a annual revenue of 126.61 Million SEK in annual revenue 2022, up 35.44% from previous year.
Devyser Diagnostics AB (publ) reported a annual revenue of 93.48 Million SEK in annual revenue 2021, up 42.31% from previous year.
Devyser Diagnostics AB (publ) reported a quarterly revenue of 48.7 Million SEK for 2024 Q3, down -8.46% from previous quarter.
Devyser Diagnostics AB (publ) reported a quarterly revenue of 50.7 Million SEK for 2024 Q1, up 11.67% from previous quarter.

Annual Revenue Chart of Devyser Diagnostics AB (publ) (2023 - 2018)

Historical Annual Revenue of Devyser Diagnostics AB (publ) (2023 - 2018)

Year	Revenue	Revenue Growth
2023	169.3 Million SEK	33.71%
2022	126.61 Million SEK	35.44%
2021	93.48 Million SEK	42.31%
2020	65.68 Million SEK	2.16%
2019	64.3 Million SEK	33.55%
2018	48.14 Million SEK	0.0%

Year	Revenue	Revenue Growth
2024 Q2	53.2 Million SEK	4.93%
2024 Q3	48.7 Million SEK	-8.46%
2024 Q1	50.7 Million SEK	11.67%
2023 FY	169.3 Million SEK	33.71%
2023 Q1	39.5 Million SEK	15.45%
2023 Q4	45.4 Million SEK	-2.78%
2023 Q3	46.7 Million SEK	23.87%
2023 Q2	37.7 Million SEK	-4.56%
2022 Q1	30.4 Million SEK	24.18%
2022 FY	126.61 Million SEK	35.44%
2022 Q3	31.2 Million SEK	0.97%
2022 Q4	34.21 Million SEK	9.66%
2022 Q2	30.9 Million SEK	1.64%
2021 Q4	24.48 Million SEK	0.0%
2021 FY	93.48 Million SEK	42.31%
2020 FY	65.68 Million SEK	2.16%
2019 FY	64.3 Million SEK	33.55%
2018 FY	48.14 Million SEK	0.0%

Peer Revenue Comparison of Devyser Diagnostics AB (publ)

Name	Revenue	Revenue Difference
AroCell AB (publ)	43.03 Million SEK	-293.364%
Immunovia AB (publ)	1.57 Million SEK	-10649.206%
Prostatype Genomics AB (publ)	1.35 Million SEK	-12385.251%
SenzaGen AB	49.87 Million SEK	-239.483%
Spermosens AB	- SEK	-Infinity%